Vishnupad
Krishna Vishnupad, Dayton, OH US
Patent application number | Description | Published |
---|---|---|
20090023692 | COMPOSITIONS FOR INHIBITING AND PREVENTING VASCULAR OCCLUSION CONTAINING NUTRITIONAL SUPPLEMENTS - Compositions for inhibiting vascular occlusion in humans comprising aspirin for inhibiting vascular occlusion which further contain nutritional supplements are disclosed. The compositions are provide in a dosage form that provides stability of the active ingredient allowing for improved shelf life. A further composition included a cholesterol-lowering agent in combination with aspirin and optionally with nutritional supplements. | 01-22-2009 |
20100285125 | DELIVERY SYSTEM FOR POORLY SOLUBLE DRUGS - The present invention relates to an oral drug delivery system for poorly soluble drugs, which can provide sustained near zero order release of poorly water soluble drugs from erodible matrix systems. Erodible matrix core is prepared using at least one active and erosion modulators in a matrix of low molecular weight and high molecular weight hydrophilic polymers in combination with a pH sensitive polymer which enable uniform hydration, controlled erosion and pH independent drug release through out GIT. The core optionally contains solubilizers. The core is optionally coated using combination of low molecular weight water soluble and water insoluble polymers, plasticizer and fillers, which provides for drug release, following a lag time, which also helps to reduce food effects in the stomach. | 11-11-2010 |
Krishna S. Vishnupad, Dayton, OH US
Patent application number | Description | Published |
---|---|---|
20080317846 | Pulsatile release histamine H2 antagonist dosage form - A unit dosage form, such as a capsule or the like, for delivering drugs into the body in a circadian release fashion comprising one or more populations of drug-containing particles (beads, pellets, granules, etc.) is disclosed. Each bead population exhibits a pre-designed rapid or sustained release profile with or without a predetermined lag time of 3 to 5 hours. Such a circadian rhythm release drug delivery system is designed to provide a plasma concentration-time profile, which varies according to physiological need at different times during the dosing period, i.e., mimicking the circadian rhythm and severity/manifestation of gastric acid secretion (and/or midnight gerd), predicted based on pharmaco-kinetic and pharmaco-dynamic considerations and in vitro/in vivo correlations. | 12-25-2008 |
Mohan Vishnupad, Easton, CT US
Patent application number | Description | Published |
---|---|---|
20110313051 | Delivery system for topical medications - The present invention is a delivery system comprising a pad and a liquid composition, comprising an insoluble dermatologically active ingredient with a viscosity that permits substantially uniform absorption of the composition onto the pad, and the pad is in then packaged in a sealed container. | 12-22-2011 |
Priya Sudarshan Vishnupad, Ewing, NJ US
Patent application number | Description | Published |
---|---|---|
20090202994 | Human single nucleotide polymorphisms in ion channels and other proteins - The invention provides polynucleotide fragments corresponding to the genomic and/or coding regions of these genes which comprise at least one polymorphic site per fragment. Allele-specific primers and probes that hybridize to these regions, and/or that comprise at least one polymorphic site are also provided. The polynucleotides, primers, and probes of the present invention are useful in phenotype correlations, paternity testing, medicine, and genetic analysis. Also provided are vectors, host cells, antibodies, and recombinant and synthetic methods for producing said polypeptides. The invention further relates to diagnostic and therapeutic methods for applying these novel polypeptides to the diagnosis, treatment, and/or prevention of various diseases and/or disorders, particularly cardiovascular diseases related to these polypeptides. The invention further relates to screening methods for identifying agonists and antagonists of the polynucleotides and polypeptides of the present invention. | 08-13-2009 |